Acuta Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Acuta Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-29,008	Closed	-$4.93M	–	32
2025 Q4	$4.93M	Buy	29,008 +3,894	+16%	+$597K	3.35%	8
2025 Q3	$3.31M	Sell	25,114 -1,169	-4%	-$140K	3.42%	10
2025 Q2	$2.79M	Buy	26,283 +16,708	+174%	+$1.81M	3.89%	10
2025 Q1	$1.19M	Buy	+9,575	New	+$1.25M	1.38%	22

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Acuta Capital Partners's JAZZ Position: Q1 2026 in Review

Acuta Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 29,008 shares — an estimated $4.93M sold.

Acuta Capital Partners first reported a position in JAZZ in Q1 2025 and held it in 4 quarters. The position peaked at $4.93M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Acuta Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Acuta Capital Partners sold 29,008 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.93M.
Acuta Capital Partners first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Acuta Capital Partners's Jazz Pharmaceuticals position peaked at $4.93M in Q4 2025.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.